Inventor
SELLMAN BRET
US16 patents
⚠️ This page may combine multiple inventors who share the name “SELLMAN BRET”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MEDIMMUNE LLC
11 patentsUS10730934B2Aug 4, 2020
Antibodies to S. aureus surface determinants
MEDIMMUNE LLC6 citations82
US9580509B2Feb 28, 2017
Multispecific and multivalent binding proteins and uses thereof
MEDIMMUNE LLC9 citations82
US11447543B2Sep 20, 2022
Antibodies to S. aureus surface determinants
MEDIMMUNE LLC1 citations71
US11059884B2Jul 13, 2021
Antibodies directed against Staphylococcus aureus leukotoxins
MEDIMMUNE LLC4 citations71
US10597439B2Mar 24, 2020
Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
MEDIMMUNE LLC4 citations71
US11168133B2Nov 9, 2021
Combinations of anti-Staphylococcus aureus antibodies
MEDIMMUNE LLC3 citations69
US11155606B2Oct 26, 2021
Antibody directed against S. aureus clumping factor a (ClfA)
MEDIMMUNE LLC3 citations69
US11168132B2Nov 9, 2021
Treatment of polybacterial infections
MEDIMMUNE LLC4 citations62
US11578119B2Feb 14, 2023
Antibodies directed against Staphylococcus aureus leukotoxins
MEDIMMUNE LLC1 citations60
US11970527B2Apr 30, 2024
Antibody directed against S. aureus clumping factor A (ClfA)
MEDIMMUNE LLC0 citations58
US12264194B2Apr 1, 2025
Decreasing Staphylococcus aureus infections in colonized patients
MEDIMMUNE LLC0 citations39
MEDIMMUNE LTD
4 patentsUS10370436B2Aug 6, 2019
Anti-pseudomonas Psl binding molecules and uses thereof
MEDIMMUNE LTD5 citations82
US11203633B2Dec 21, 2021
Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv
MEDIMMUNE LTD2 citations71
US10844114B2Nov 24, 2020
Anti-Pseudomonas Psl binding molecules and uses thereof
MEDIMMUNE LTD3 citations71
US12428473B2Sep 30, 2025
Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
MEDIMMUNE LTD0 citations61